Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer

Affiliations

¹ Division of Hematology/Oncology, Gastrointestinal Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

Editorial

Andrew H Ko. Hepatobiliary Surg Nutr. 2018 Oct.

. 2018 Oct;7(5):406-408.

doi: 10.21037/hbsn.2018.06.02.

¹ Division of Hematology/Oncology, Gastrointestinal Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H. Sinn M, et al. J Clin Oncol. 2017 Oct 10;35(29):3330-3337. doi: 10.1200/JCO.2017.72.6463. Epub 2017 Aug 17. J Clin Oncol. 2017. PMID: 28817370 Clinical Trial.

1. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-77. 10.1001/jama.297.3.267 - DOI - PubMed
1. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6. 10.1200/JCO.2006.07.9525 - DOI - PubMed
1. Sinn M, Bahra M, Liersch T, et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. J Clin Oncol 2017;35:3330-7. 10.1200/JCO.2017.72.6463 - DOI - PubMed
1. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012;13:1225-33. 10.1016/S1470-2045(12)70509-0 - DOI - PubMed
1. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012;307:1383-93. 10.1001/jama.2012.385 - DOI - PMC - PubMed